Aurinia Pharmaceuticals Inc (AUPH) Fair Value & Analysis
Healthcare · US · Market cap $2.0B
Aurinia Pharmaceuticals Inc
AUPH · US
Fair value as of: Jul 13, 2026
From 24 valuation models · updated 4 days ago
Fair value updated Jul 13, 2026, revised from $25.39 to $25.69 (+1.2%) since Jun 24, 2026. Share price −1.7% over the past month.
Price vs Fair Value (12 months)
12‑month range $8.62 – $18.62 · fair‑value band $14.67 – $45.01 · the $15.94 price screens below the $25.69 fair value. As of Jul 13, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Aurinia Pharmaceuticals Inc (AUPH) currently trades at $15.94, while our model-based Fair Value estimate is $25.69, implying the stock looks roughly 61.2% undervalued today. We read business quality at 77/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Aurinia Pharmaceuticals Inc generated revenue of $298M at a net margin of 100.0%. Revenue grew 24.4% year over year. It earns a return on equity of 65.0%. The balance sheet holds a net cash position of $5.4M. Fundamentals as of Jul 13, 2026
Our scenario range runs from $14.67 (bear case) to $45.01 (bull case); at $15.94, the current price sits within that range. The share trades about 6% below its 52-week high and 119% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside, at 61%, AUPH screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 13, 2026. TTM = trailing twelve months.
About the company
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Aurinia Pharmaceuticals Inc reported revenue of $283M in FY2025 versus $45.6M in FY2021, a compound +57.8%/yr. Reported net income was $287M in FY2025.
Is AUPH fairly valued? → Check now
Recent news
- Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?
- Aurinia (AUPH) Moves 6.5% Higher: Will This Strength Last?
- Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?
- Aurinia Pharmaceuticals and Four More Stocks See Activist Action
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection, not financial advice.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | 7,746 MXN | 5,617 MXN | -27% |
| Regeneron Pharmaceuticals, Inc REGN | $601.65 | $577.20 | -4% |
| UCB SA UCB | €247.60 | €180.06 | -27% |
| argenx SE ARGNF | $935.38 | $382.64 | -59% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,011,109 KRW | +1% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$27.80 | R$23.67 | -15% |
| WuXi Biologics (Cayman) Inc 2269 | HK$37.56 | HK$26.11 | -30% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Aurinia Pharmaceuticals Inc (AUPH) undervalued?
What is the fair value of AUPH?
What is the quality score of AUPH?
What is the revenue of Aurinia Pharmaceuticals Inc (AUPH)?
What is the net profit margin of AUPH?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Unlock the full Aurinia Pharmaceuticals Inc analysis, and try Pro free
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.